文献速递泌尿男性生殖肿瘤

前列腺癌适度大分割调强放疗与立体定向体部放疗对比(PACE-C):随机、开放标签、3期非劣效试验的早期毒性结果

Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial.
PubMed 文献 · Lancet Oncol · 2025-06-12

PACE-C是一项在53家医院开展的随机、开放标签、3期非劣效试验,纳入中高危前列腺腺癌患者1208例,随机接受适度大分割放疗(MHRT)或立体定向体部放疗(SBRT)。早期(放疗期间或完成后12周内)RTOG 2级及以上泌尿生殖毒性和胃肠毒性在两组间无显著差异,SBRT与MHRT早期RTOG毒性相似。

要点

  • 早期RTOG 2级及以上泌尿生殖毒性:MHRT组27% vs SBRT组28%,绝对差异0.5%(95%CI -4.7至5.7;p=0.89)。
  • 早期RTOG 2级及以上胃肠毒性:MHRT组11% vs SBRT组13%,绝对差异1.4%(95%CI -2.5至5.2;p=0.53)。
  • CTCAE 2级及以上胃肠毒性:MHRT组10% vs SBRT组17%(p=0.0011);CTCAE 2级及以上泌尿生殖毒性:MHRT组28% vs SBRT组34%(p=0.050)。

核心结论

  • 尽管SBRT治疗方案加速且治疗体积大于PACE-B,SBRT与MHRT的早期RTOG毒性发生率相似。

研究设计与样本

  • 随机、开放标签、3期非劣效PACE-C试验,在英国、爱尔兰共和国和新西兰的53家医院开展。
  • 招募年龄至少18岁、组织学确诊的中危或高危前列腺腺癌男性(T1-T3a、Gleason 7-8、前列腺特异性抗原10-30 ng/mL),WHO体能状态0-2。
  • 参与者按1:1中央随机分配至MHRT(60 Gy;20次每日分割,4周内完成)或SBRT(36.25 Gy;5次每日或隔日分割,1-2周内完成),并按中心和风险组分层。
  • 计划进行6个月雄激素剥夺治疗,并于放疗开始前启动。
  • 主要结局为生化或临床失败无病生存,数据尚未成熟;本次预先计划的安全性分析共同主要终点为放疗期间或完成后12周内(早期或急性期)RTOG 2级及以上胃肠和泌尿生殖毒性的百分比。

主要发现

  • 2019年11月13日至2022年6月24日,共1208例参与者被随机分配(MHRT组601例,SBRT组607例);608例接受MHRT,584例接受SBRT,纳入分析。
  • 1136例(95%)为白人,20例(2%)为黑人或英国黑人,17例(1%)为亚洲人或英国亚洲人,7例(1%)为中国人或其他。
  • 早期RTOG 2级及以上泌尿生殖毒性:MHRT组608例中166例(27%,95%CI 23.8-31.1)vs SBRT组582例中162例(28%,95%CI 24.3-31.7),绝对差异0.5%(95%CI -4.7至5.7;p=0.89)。
  • CTCAE 2级及以上泌尿生殖毒性:MHRT组604例中170例(28%)vs SBRT组581例中195例(34%)(p=0.050);CTCAE 3级泌尿生殖毒性:MHRT组3例(<1%)vs SBRT组3例(1%)。
  • CTCAE 2级及以上胃肠毒性:MHRT组604例中60例(10%)vs SBRT组581例中96例(17%)(p=0.0011);CTCAE 3级胃肠毒性:MHRT组3例(<1%)vs SBRT组4例(1%)。

局限性

  • 主要结局(生化或临床失败无病生存)数据尚未成熟。
  • 晚期毒性和疗效数据尚待随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Moderately hypofractionated radiotherapy (MHRT) is a standard treatment for prostate cancer. Stereotactic body radiotherapy (SBRT) is also effective, and has been shown to be non-inferior to MHRT in a lower-risk group of patients who did not require hormone therapy (PACE-B), but randomised data on toxicity for higher-risk patients are lacking. We aimed to compare the early toxicity of MHRT and SBRT. METHODS: The randomised, open-label, phase 3, non-inferiority PACE-C trial, conducted at 53 hospitals across the UK, Republic of Ireland, and New Zealand, recruited men aged at least 18 years with intermediate-risk or high-risk histologically confirmed prostate adenocarcinoma (T1-T3a, Gleason 7-8, and prostate specific antigen 10-30 ng/mL) and with WHO performance status of 0-2. Participants were centrally randomly assigned (1:1; non-masked; permuted block size of four and six; stratified by centre and risk group) to MHRT (60 Gy; 20 daily fractions over 4 weeks) or SBRT (36·25 Gy; five daily or alternate day fractions; over 1-2 weeks) with an additional mandatory clinical target volume dose target of 40 Gy (no margin) to the prostate, and proximal 1 cm of seminal vesicles. 6 months of androgen deprivation therapy was planned and was started before commencement of radiotherapy. The primary outcome of PACE-C is freedom from biochemical or clinical failure, the data for which are not yet mature. The co-primary endpoints for this preplanned safety analysis were the percentages of Radiation Therapy Oncology Group (RTOG) grade 2 or worse gastrointestinal and genitourinary toxicities at any point during or within 12 weeks of completion of radiotherapy (the early or acute period). Analyses are by treatment received, with participants included if they had one or more fractions of MHRT or SBRT, regardless of their allocated treatment. Late toxicity and efficacy data are awaited as the trial remains in follow-up. The study was prospectively registered with ClinicalTrials.gov, NCT01584258. FINDINGS: Between Nov 13, 2019, and June 24, 2022, 1208 participants were randomly assigned (601 to MHRT and 607 to SBRT). 608 patients received MHRT and 584 received SBRT, and thus were included in the study analysis. 1136 (95%) of 1192 patients were White, 20 (2%) were Black or Black British, 17 (1%) were Asian or Asian British, and seven (1%) were Chinese or other. During the early period (within 12 weeks of treatment), the co-primary endpoint of RTOG grade 2 or worse genitourinary toxicity was observed in 166 (27%) of 608 patients (95% CI 23·8 to 31·1) receiving MHRT and 162 (28%) of 582 patients (24·3 to 31·7) after SBRT (absolute difference 0·5%, 95% CI -4·7 to 5·7; p=0·89). For grade 2 or worse genitourinary Common Terminology Criteria for Adverse Events (CTCAE), 170 (28%) of 604 patients had events after MHRT and 195 (34%) of 581 patients had events after SBRT (p=0·050). Grade 3 CTCAE genitourinary toxicity was observed in three (<1%) patients receiving MHRT and three (1%) patients receiving SBRT. For grade 2 or worse gastrointestinal CTCAE, 60 (10%) of 604 patients had an event after MHRT and 96 (17%) of 581 patients had an event after SBRT (p=0·0011). Grade 3 CTCAE gastrointestinal toxicity was observed in three (<1%) patients receiving MHRT and four (1%) patients receiving SBRT. During the early period, the co-primary endpoint of RTOG grade 2 or worse gastrointestinal toxicity was observed in 69 (11%) of 608 patients (95% CI 9·0 to 14·2) receiving MHRT and 74 (13%) of 584 patients (10·2 to 15·8) receiving SBRT (absolute difference 1·4%, 95% CI -2·5 to 5·2; p=0·53). There were no treatment-related deaths. INTERPRETATION: Despite an accelerated treatment schedule and a larger treated volume than PACE-B, SBRT and MHRT had similar rates of early RTOG toxicity. FUNDING: The Royal Marsden Cancer Charity.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Tree AC, Hinder V, Chan A, et al. Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2025. PMID: 40517778. doi:10.1016/S1470-2045(25)00205-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。